ResMed stock snapshot after recent trading move

ResMed (RMD) has drawn fresh attention after a recent uptick in trading, with the stock closing at US$200.29 as investors reassess the company’s sleep and respiratory care footprint.

The latest 0.85% 1 day share price gain sits against a weaker backdrop, with the share price down 18.19% year to date and the 1 year total shareholder return declining 20.74%. This suggests recent interest follows a period of fading momentum.

If ResMed’s move has you rethinking opportunities in healthcare technology, this could be a good moment to broaden your search and review 39 healthcare AI stocks

With ResMed stock down over the past year but trading at a discount to one analyst price target and some intrinsic value estimates, you have to ask: Is this a genuine entry point, or is the market already pricing in future growth?

Most Popular Narrative: 23.1% Undervalued

ResMed’s most followed narrative points to a fair value of $260.60 versus the last close at $200.29, framing the stock as materially undervalued on analyst assumptions.

Strategic investments in expanding the diagnosis and treatment funnel, including acquisitions like VirtuOx, Ectosense, and Somnoware, are improving patient flow from screening to therapy, positioning ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market, supporting long-term revenue growth.

Analysts are not just guessing. Their fair value hangs on a specific glide path for revenue, profit margins and the earnings multiple they think ResMed can support. Curious which assumption really moves the needle and how tightly it all ties back to that $260.60 figure.

Result: Fair Value of $260.60 (UNDERVALUED)

However, investors also need to weigh risks, including potential pricing pressure from reimbursement changes and competition from alternative sleep apnea therapies that could challenge parts of the ResMed narrative.

Next Steps

The article so far highlights mixed sentiment around ResMed, so if this has caught your attention, consider reviewing the information promptly and weigh the data for yourself before opinions settle. To see what optimism is already reflected in the numbers, take a closer look at the 4 key rewards

Looking for more investment ideas beyond ResMed?

If ResMed has sharpened your focus, do not stop here. Use the Simply Wall St screener to uncover other stocks that might better match your investing checklist.

• Target potential mispricings by reviewing companies flagged as strong value candidates in the 44 high quality undervalued stocks.
• Prioritise resilience by scanning for companies with robust financial footing using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for opportunities that the crowd may be overlooking by checking the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.